Cargando…
Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance
BACKGROUND: Doravirine has a unique resistance profile but how this profile might increase its usefulness beyond first-line therapy in persons with susceptible viruses has not been well studied. We sought to determine scenarios in which doravirine would retain activity against isolates from ART-naïv...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903540/ https://www.ncbi.nlm.nih.gov/pubmed/36750835 http://dx.doi.org/10.1186/s12981-023-00503-5 |
_version_ | 1784883492452040704 |
---|---|
author | Rhee, Soo-Yon Schapiro, Jonathan M. Saladini, Francesco Zazzi, Maurizio Khoo, Saye Shafer, Robert W. |
author_facet | Rhee, Soo-Yon Schapiro, Jonathan M. Saladini, Francesco Zazzi, Maurizio Khoo, Saye Shafer, Robert W. |
author_sort | Rhee, Soo-Yon |
collection | PubMed |
description | BACKGROUND: Doravirine has a unique resistance profile but how this profile might increase its usefulness beyond first-line therapy in persons with susceptible viruses has not been well studied. We sought to determine scenarios in which doravirine would retain activity against isolates from ART-naïve persons with transmitted drug resistance (TDR) and to identify gaps in available doravirine susceptibility data. METHODS: We analyzed published in vitro doravirine susceptibility data and applied the results to 42,535 RT sequences from ART-naïve persons published between 2017 and 2021. NNRTI drug resistance mutations (DRMs) were defined as those with a Stanford HIV Drug Resistance Database doravirine penalty score either alone or in combination with other mutations. RESULTS: V106A, Y188L, F227C/L, M230L, and Y318F were associated with the greatest reductions in doravirine susceptibility. However, several NNRTI DRMs and DRM combinations lacking these canonical resistance mutations had > tenfold reduced susceptibility including G190E, one isolate with G190S, three isolates with L100I + K103N, one isolate with K103N + P225H, and isolates with L100I + K103N + V108I and K101E + Y181C + G190A. Of the 42,535 ART-naïve sequences, 3,374 (7.9%) contained a NNRTI DRM of which 2,788 (82.6%) contained 1 DRM (n = 33 distinct mutations), 426 (12.6%) contained 2 DRMs (79 distinct pairs of mutations), and 143 (4.2%) contained ≥ 3 DRMs (86 distinct mutation patterns). Among the 2,788 sequences with one DRM, 112 (4.0%) were associated with ≥ 3.0-fold reduced doravirine susceptibility while 2,625 (94.2%) were associated with < 3.0-fold reduced susceptibility. Data were not available for individual NNRTI DRMs in 51 sequences (1.8%). Among the 426 sequences with two NNRTI DRMs, 180 (42.3%) were associated with ≥ 3.0 fold reduced doravirine susceptibility while just 32 (7.5%) had < 3.0 fold reduced susceptibility. Data were not available for 214 (50.2%) sequences containing two NNRTI DRMs. CONCLUSIONS: First-line therapy containing doravirine plus two NRTIs is expected to be effective in treating most persons with TDR as more than 80% of TDR sequences had a single NNRTI DRM and as more than 90% with a single DRM were expected to be susceptible to doravirine. However, caution is required for the use of doravirine in persons with more than one NNRTI DRM even if none of the DRMs are canonical doravirine-resistance mutations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12981-023-00503-5. |
format | Online Article Text |
id | pubmed-9903540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99035402023-02-08 Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance Rhee, Soo-Yon Schapiro, Jonathan M. Saladini, Francesco Zazzi, Maurizio Khoo, Saye Shafer, Robert W. AIDS Res Ther Research BACKGROUND: Doravirine has a unique resistance profile but how this profile might increase its usefulness beyond first-line therapy in persons with susceptible viruses has not been well studied. We sought to determine scenarios in which doravirine would retain activity against isolates from ART-naïve persons with transmitted drug resistance (TDR) and to identify gaps in available doravirine susceptibility data. METHODS: We analyzed published in vitro doravirine susceptibility data and applied the results to 42,535 RT sequences from ART-naïve persons published between 2017 and 2021. NNRTI drug resistance mutations (DRMs) were defined as those with a Stanford HIV Drug Resistance Database doravirine penalty score either alone or in combination with other mutations. RESULTS: V106A, Y188L, F227C/L, M230L, and Y318F were associated with the greatest reductions in doravirine susceptibility. However, several NNRTI DRMs and DRM combinations lacking these canonical resistance mutations had > tenfold reduced susceptibility including G190E, one isolate with G190S, three isolates with L100I + K103N, one isolate with K103N + P225H, and isolates with L100I + K103N + V108I and K101E + Y181C + G190A. Of the 42,535 ART-naïve sequences, 3,374 (7.9%) contained a NNRTI DRM of which 2,788 (82.6%) contained 1 DRM (n = 33 distinct mutations), 426 (12.6%) contained 2 DRMs (79 distinct pairs of mutations), and 143 (4.2%) contained ≥ 3 DRMs (86 distinct mutation patterns). Among the 2,788 sequences with one DRM, 112 (4.0%) were associated with ≥ 3.0-fold reduced doravirine susceptibility while 2,625 (94.2%) were associated with < 3.0-fold reduced susceptibility. Data were not available for individual NNRTI DRMs in 51 sequences (1.8%). Among the 426 sequences with two NNRTI DRMs, 180 (42.3%) were associated with ≥ 3.0 fold reduced doravirine susceptibility while just 32 (7.5%) had < 3.0 fold reduced susceptibility. Data were not available for 214 (50.2%) sequences containing two NNRTI DRMs. CONCLUSIONS: First-line therapy containing doravirine plus two NRTIs is expected to be effective in treating most persons with TDR as more than 80% of TDR sequences had a single NNRTI DRM and as more than 90% with a single DRM were expected to be susceptible to doravirine. However, caution is required for the use of doravirine in persons with more than one NNRTI DRM even if none of the DRMs are canonical doravirine-resistance mutations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12981-023-00503-5. BioMed Central 2023-02-07 /pmc/articles/PMC9903540/ /pubmed/36750835 http://dx.doi.org/10.1186/s12981-023-00503-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Rhee, Soo-Yon Schapiro, Jonathan M. Saladini, Francesco Zazzi, Maurizio Khoo, Saye Shafer, Robert W. Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance |
title | Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance |
title_full | Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance |
title_fullStr | Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance |
title_full_unstemmed | Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance |
title_short | Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance |
title_sort | potential role of doravirine for the treatment of hiv-1-infected persons with transmitted drug resistance |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903540/ https://www.ncbi.nlm.nih.gov/pubmed/36750835 http://dx.doi.org/10.1186/s12981-023-00503-5 |
work_keys_str_mv | AT rheesooyon potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance AT schapirojonathanm potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance AT saladinifrancesco potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance AT zazzimaurizio potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance AT khoosaye potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance AT shaferrobertw potentialroleofdoravirineforthetreatmentofhiv1infectedpersonswithtransmitteddrugresistance |